Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Tokyo Gas Co., Ltd. engages in the provision of city gas and other gas-related products. It operates through the following segments: Gas, Electric Power, Overseas Business, Energy-related, Real Estate, and Others. The Gas segment produces, supplies, and sells city gas and liquid gas. The Electric Power segment handles electric power services. The Overseas Business segment deals with overseas resource development, investment, and energy. The Energy-related segment includes engineering solutions, gas appliances, and gas construction works. The Real Estate segment leases and manages land and buildings. The Others segment includes information processing service and shipping businesses. The company was founded by Eiichi Shibusawa on October 1, 1885 and is headquartered in Tokyo, Japan.

Boehringer Ingelheim Corporate Center GmbH, part of C.H. Boehringer Sohn AG & Co. KG, is a company headquartered in Ingelheim am Rhein, Germany. The firm leases real estate properties. It was founded in 2016.

Manufactures and distributes hair coloring products, cosmetics and medical supplies

Global Gillette manufactures and sells razors, personal care products, batteries, and oral care products. It also provides selected female grooming products, wet shaving, hair epilating devices, batteries, and toothbrushes. Global Gillette was founded in 1901 and is headquartered in Boston, MA.

The Upjohn Company was a pharmaceutical manufacturing firm founded in 1886 in Kalamazoo, Michigan, by Dr. William E. Upjohn, an 1875 graduate of the University of Michigan medical school. The company was originally formed to make friable pills, which were specifically designed to be easily digested. These could be "reduced to a powder under the thumb", a strong marketing argument at the time.

Guangdong Jiu Ming Pharmaceutical Co., Ltd., established on 2001-10-16, Business scope includes licensed projects:pharmaceutical production;Production of Class II Medical Devices.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Production of Class I Medical Devices.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

E. Merck KG operates as a holding company with interest in pharmaceutical preparations. It acts as a general partner that holds the majority of shares of the public company Merck KGaA. Merck KG is the parent company of all Merck companies yet it does not have any operating businesses itself. It makes the entrepreneurial policy decisions for the Merck Group. The company is headquartered in Darmstadt, Germany.

Konkuk University Industry-Academic Cooperation Foundation increases the competitiveness of industries by linking company and university.

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA

Yamanouchi Pharmaceutical Co. Ltd. manufactures and markets drugs, quasi-drugs and medical devices. It used to promote collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. It was founded in 1923. The company was headquartered in Tokyo, JP

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

The enterprise is a biotechnology R&D enterprise founded by returned overseas students in Zhangjiang Hi Tech Park, Shanghai in 2002. Main business: 1) Preparation, production and characterization of biomedical materials; 2) Evaluation of drug metabolism and interaction in vitro; 3) Evaluation of drug transport and interaction in vitro; 4) Bioartificial liver dialysis therapy; 5) Research and development of synergistic mechanism of metabolic/transport interaction of traditional Chinese medicine; 6) Individualized medication based on drug interactions. Using in vitro biotechnology as a platform, we strictly follow the corresponding guiding principles of the drug administration department, relevant medical ethics and animal rights, fully implement quality monitoring, and provide in vitro drug ADMET evaluation services, products and corresponding services for the new drug innovation team with high quality and punctuality. The following outsourcing services provided support the screening and optimization of new drugs in the early discovery stage, the design of preclinical studies of new drugs and clinical approval. Many of these projects have successfully passed the clinical approval of the Chinese drug regulatory authorities and the US FDA. • In Vitro and Ex Vivo CYP450 Inhibition / Induction • Metabolic stability / Metabolite Identification / Metabolite Pathway Identification • Transporter Evaluation: Substrate and inhibitors • Permeability / solubility / Cytotoxicity / Protein binding The following in vitro biological materials and reagents provided reflect high quality, timely delivery, reasonable price and high service (pre-sales consultation and after-sales service) • Cryopreserved primary hepatocytes/microsomes/S9: human (Mongolian/Caucasian) and experimental animals (mice, rats, guinea pigs, rabbits, dogs, monkeys, pigs, cattle, chickens) • Recombinant drug metabolizing enzymes • Induced rat liver S9 fraction for mutagenicity studies • Drug transporters: ABC transporter capsule/SLC transporter cell line • Reagents for drug metabolism and transport: substrate, product, inhibitor, inducer

Sucampo GmbH, a subsidiary of Mallinckrodt Plc, is a Swiss company located in Zug that manufactures and distributes pharmaceuticals and health care products. It was founded by Ryuji Ueno and Sachiko Kuno. On December 29, 2010 Sucampo Pharmaceuticals, Inc., now a subsidiary of Mallinckrodt Plc acquired Sucampo GmbH for $120.00 million.